COST-EFFECTIVENESS OF MYLOOP POWERED BY CAMAPS FX IN PAEDIATRIC TYPE 1 DIABETES: AN ANALYSIS FROM THE AUSTRIAN HEALTHCARE SYSTEM PERSPECTIVE
Author(s)
Sabine Hofer, MD,PhD1, Torben Biester, MD2, Alexander Eckert, MD3, Stefanie Lanzinger, MD, PhD3, Elke Fröhlich-Reiterer, MD, PhD4, Birgit Rami-Merhar, MD, MBA5, Giovanni Brusaferri, MSc, MBA6, Aesha Khan Miron, MSc6, Roberto Monfermoso, MSc6, Maria-Eleni Syleouni, MA, MSc, PhD6.
1Medical University of Innsbruck, Department of Pediatrics, Innsbruck, Austria, 2Department of Pediatric and Adolescent Medicine, Braunschweig Municipal Hospital, Brunswick, Germany, 3Ulm University, Institute of Epidemiology and Medical Biometry, Ulm, Germany, 4Division of General Paediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria, 5Department of Pediatric and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria, 6mylife Diabetes Care AG, Burgdorf, Switzerland.
1Medical University of Innsbruck, Department of Pediatrics, Innsbruck, Austria, 2Department of Pediatric and Adolescent Medicine, Braunschweig Municipal Hospital, Brunswick, Germany, 3Ulm University, Institute of Epidemiology and Medical Biometry, Ulm, Germany, 4Division of General Paediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria, 5Department of Pediatric and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria, 6mylife Diabetes Care AG, Burgdorf, Switzerland.
OBJECTIVES: There is limited evidence on the long-term use of automated insulin delivery (AID) treatment starting in childhood, which represents a critical period of neurodevelopment where tight glycaemic control and high-precision therapy are essential1. The aim of this study was to analyse the cost-effectiveness of T1D paediatrics transitioning from multiple daily injections (MDI) plus continuous glucose monitoring (CGM) to myloop powered by CamAPS FX. Additionally, long-term clinical impact and economic consequences were evaluated from the Austrian healthcare system perspective.
METHODS: Cohort baseline clinical characteristics (age <21y, ≥1 year of T1D) and treatment effect observed from the DPV registry2-3 (German and Austrian cohort) were used for the cost-effectiveness analysis; mean age 12.2 years, baseline HbA1c 7.9%, a -0.8% initial HbA1c reduction during the first year after transitioning to myLoop CamAPS FX. “Fear of hypo reduction” utility gain was applied for AID use4. Clinical and economic outcomes were projected over 55 years. The IQVIA Core Diabetes Model v.10 was used with direct costs sourced from published literature, inflated to 2025 values. A willingness-to-pay threshold of €20,000 per quality-adjusted life year (QALY) was assumed5.
RESULTS: Transitioning from MDI+CGM to myLoop powered by CamAPS FX was associated with 36% (95% Confidence Interval (CI): 35.9%-36.1%) reduction in all diabetes-related complications and 2.1 (95% CI: 2.06-2.07) mean QALYs gained. MyLoop CamAPS FX was a cost-effective treatment when assessed against the WTP threshold with an incremental cost-effectiveness ratio (ICER) of €12,370 per QALY gained for T1D paediatric patients.
CONCLUSIONS: Early initiation on myLoop powered by CamAPS FX during childhood is projected to deliver lifelong health impact, significantly reducing and delaying complications and improving quality of life across the life course, while remaining cost-effective for the Austrian healthcare system. These findings support early intervention programs to ensure early access to AID therapy before this critical window closes.
METHODS: Cohort baseline clinical characteristics (age <21y, ≥1 year of T1D) and treatment effect observed from the DPV registry2-3 (German and Austrian cohort) were used for the cost-effectiveness analysis; mean age 12.2 years, baseline HbA1c 7.9%, a -0.8% initial HbA1c reduction during the first year after transitioning to myLoop CamAPS FX. “Fear of hypo reduction” utility gain was applied for AID use4. Clinical and economic outcomes were projected over 55 years. The IQVIA Core Diabetes Model v.10 was used with direct costs sourced from published literature, inflated to 2025 values. A willingness-to-pay threshold of €20,000 per quality-adjusted life year (QALY) was assumed5.
RESULTS: Transitioning from MDI+CGM to myLoop powered by CamAPS FX was associated with 36% (95% Confidence Interval (CI): 35.9%-36.1%) reduction in all diabetes-related complications and 2.1 (95% CI: 2.06-2.07) mean QALYs gained. MyLoop CamAPS FX was a cost-effective treatment when assessed against the WTP threshold with an incremental cost-effectiveness ratio (ICER) of €12,370 per QALY gained for T1D paediatric patients.
CONCLUSIONS: Early initiation on myLoop powered by CamAPS FX during childhood is projected to deliver lifelong health impact, significantly reducing and delaying complications and improving quality of life across the life course, while remaining cost-effective for the Austrian healthcare system. These findings support early intervention programs to ensure early access to AID therapy before this critical window closes.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
MT30
Topic
Clinical Outcomes, Economic Evaluation, Medical Technologies
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas